FGFR1 and cancer: AZD4547 is a potent and selective small-molecule inhibitor of FGFR1 with an IC50 value of 0.2 nM and currently in phase II and III clinical trials for the treatment of cancer (ClinicalTrials.gov Identifier: NCT02154490).